

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/018463

International filing date: 10 June 2004 (10.06.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/477,561
Filing date: 11 June 2003 (11.06.2003)

Date of receipt at the International Bureau: 19 August 2004 (19.08.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1211289

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME;

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

August 12, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/477,561
FILING DATE: June 11, 2003
RELATED PCT APPLICATION NUMBER: PCT/US04/18463

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office

06-12-03

60477561.061

Approved
\$
C-C

PTO/SB/16 (05-03)


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 327589725 US

17661 U.S. PTO

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Frederick Ralph		Kettinger		Norrington, PA	
Additional inventors are being named on the <u>one</u> separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
PHARMACEUTICAL DOSAGE FORMS HAVING OVERT AND COVERT MARKINGS FOR IDENTIFICATION AND AUTHENTICATION					
Direct all correspondence to:					
CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number	20311		 20311		
OR Type Customer Number here					
<input type="checkbox"/> Firm or Individual Name	PATENT TRADEMARK OFFICE				
Address					
Address					
City					
Country					
State					
Telephone					
ZIP					
Fax					
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification	Number of Pages	15	<input type="checkbox"/> CD(s), Number		
<input type="checkbox"/> Drawing(s)	Number of Sheets	2	<input type="checkbox"/> Other (specify)		
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input type="checkbox"/> A check or money order is enclosed to cover the filing fees. <input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 02-2275 <input checked="" type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
					FILING FEE AMOUNT (\$) 160.00
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No. <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:					

Respectfully submitted

[Page 1 of 2]

SIGNATURE

Date 6/11/03

TYPED or PRINTED NAME Michael N. Mercanti

REGISTRATION NO.
(If appropriate)

33,966

TELEPHONE 212-661-8000

Docket Number:

525.1089

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

60477561.061103

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (05-03)
Approved for use through 4/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number 525.1089

INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Charles	Fields	Kent, England
Thomas P.	Farrell	Warrington, PA

[Page 2 of 2]

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

60477561 .061103

"EXPRESS MAIL" Mailing Label Number EV 327589725 US

Date of Deposit: June 11, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450



Michael N. Marcanti

525.1089

**PHARMACEUTICAL DOSAGE FORMS HAVING OVERT AND COVERT
MARKINGS FOR IDENTIFICATION AND AUTHENTICATION**

5 **Field of the Invention**

This invention relates to pharmaceutical oral dosage forms having unique markings which allow it to be tracked and identified after leaving manufacturers' premises. Specifically, the invention relates to the use of visible indicators such as bar codes as well as covert markers which are imprinted or etched onto tablets and the like
10 for the purposes of identification and authentication of a solid dose form in combination with or separate from film coated systems and / color film coated systems.

BACKGROUND OF THE INVENTION

In recent years there has been a need for increased control and tracking of
15 pharmaceutical dosage forms. There have been suggestions to implement various tracking devices such as bar codes and hologram, etc on the bulk packages and unit dosage packs sent to pharmacies from manufacturers. Others have suggested employing bar codes on oral dosage forms as a way of increasing the tracking of the tablets. If the tablets could be scanned before being given to the patient by the healthcare provider, it is
20 believed that there would be a significant reduction in medication administration errors in hospitals. Further information regarding the efforts in this regard are found, for example in US Patent Nos. 5,942,444, 5,992,742 and 6,543,692.

SUMMARY OF THE INVENTION

25 In one aspect of the invention there is provided an oral solid dosage form such as a tablet having printed or etched markings thereon to identify and or authenticate the dosage form and/or drug contained therein. The inventive dosage form includes

- a) a core portion having sufficiently low friability to receive a printed or etched marking on a surface thereof; and

b) a readable or detectable printed or etched marking on the surface of the core which provides information allowing the identification/authentication of the oral dosage form.

5 In preferred aspects of this embodiment, a bar code, more preferably, a 2D data matrix bar code is printed or etched on a surface of the tablet or solid dose form. For purposes of the present invention, the term "tablet" shall be understood to include all pharmaceutically acceptable solid dosages forms, including oral and non-oral compressed tablets, caplets, enrobed tablets, hard or soft (gelatin) capsules, press fit tablets and the like.

10 Additional embodiments of the invention include methods of preparing the marked dosage forms and methods of identifying and/ or authenticating solid dosage forms. The method of preparing the uniquely identifiable oral dosage forms includes applying a readable printed or etched marking capable of providing identification authentication criteria on the surface an oral solid dosage form by the steps of:

- 15 a) providing a pharmaceutically acceptable core portion having sufficiently low friability to receive a printed or etched marking on a surface thereof; and
b) applying a readable printed or etched marking on the surface of said core. said marking of said oral dosage form.

In preferred aspects of this embodiment, the markings are applied using a pad printer or
20 ink jet printer.

As a result of the present invention, there is provided a technology that allows a pharmaceutical company to distinguish among tablets and other dosage forms for the purpose of reducing medication errors and to enhance patient compliance. Pharmacies and hospitals or the like can also benefit from this identification system since the system
25 does not rely on indicators which are easily copied by counterfeiters such as color, shape or word markings on tablets.

Another advantage of the present invention is that by employing covert marking such as molecular bar codes, the inventors have developed the ability to covertly
30 authenticate pharmaceutical dosage forms using globally approved pharmaceutical markers. When combined with overt markings, the artisan has solid dosage forms which are always traceable and insure a high degree assurance that the intended dose is received

by the patient to whom it is prescribed. The dosage forms of the present invention thus preferably allow for visual identification, electronic scanning identification, and immediate evidential (qualitative) in-field chemical identification. All of these technologies are commercially available at the present time and currently employ
5 equipment that is available. Since the markings are applied directly to the dosage form itself, there is an added degree of assurance over similar markings applied to packaging materials such as manufacturers' containers or even unit dose packages, each of which must ultimately be separated from the dosage form prior to ingestion.

10 BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1-2 are photographs showing compressed tablets prepared in accordance with the present invention.

DETAILED DESCRIPTION

15 The overt and covert markers of the present invention can be used for simple identification and authentication of the drug or solid dose form and may also be used as a chemical bar code system to provide information that may include but not be limited to:
source of manufacture, date of manufacture, manufacturing lot number, intended point of retail sale to comply with regulatory requirements, date of expiration, etc.

20 The invention includes the printed or etched bar code preferably film coated and / or color film coated to enable the commercial reliability of the imprinting or etching process to:

prevent ink bleed, enhance resolution, eliminate tablet dusting, eliminate and or reduce printing discontinuities and enhance reliability of electronic and or other scan
25 identification techniques, equipment and processes. While a wide variety of tablet film coatings can be employed in carrying out the invention, preferred film coatings are capable of adhering to both the tablet core, which is typically a microcrystalline cellulose-based compressed tablet, and the marking which is preferably ink-based. A non-limiting list of suitable film coatings include those available from Colorcon under the
30 OPADRY® and OPAGLOS® brand names. Generally, however, such suitable film

coatings well known to those of ordinary skill will be based on a blend of a cellulosic polymer or polyvinyl acetate (PVA), plasticizer and other film coating ingredients.

The amount of film coating applied to the core before the marking is applied will depend upon the needs of the artisan, the type of marking applied and other parameters
5 know to those of ordinary skill. Generally, the tablet cores are coated to a weight gain of from about 1 to about 5 % by weight. Preferably, the film coatings are applied to weight gains of from about 2 to about 4.

The invention includes various printing and etching processes, preferably a pad printing process or an ink jet printing process. Laser etching of the tablet surface and or
10 the film coated surface is a technology included in this patent suggestion.

In one preferred embodiment, the tablets are pad printed using an apparatus such as that described in PCT published application WO01/30573 A1, the contents of which are incorporated herein by reference. Such devices are capable of accurately and
15 uniformly applying printing symbols and the like using a pad printer onto compressed tablets which are oriented on a conveyor unit at relatively high speed. The apparatus are also available from Printing International of Belgium.

As an alternative to the pad printing, ink jet printing of the markers onto the tablets can be employed. In such aspects of the invention, an ink jet printer replaces the pad printing device and the tablets are conveyed to the printer for marking(s). The ink jet
20 printer allows for further identification of the tablets such as serialization (numbering of the tablets consecutively, etc.) without the need to stop the continuous printing process to change the printing pad or other marking device. Such modifications are said to be made in real time and allow a myriad of changes to be made. One such ink jet printer is available from Domino of Cambridge, UK. Alternatives include piezojet inkjet systems
25 such those available from Xaar Technology Limited of Cambridge, UK or any other devices capable of delivering high resolution images onto oral solid dosage forms. Regardless of the printing apparatus employed, the ink selected for marking the tablets must be ingestible and meet all regulatory requirements for use in the pharmaceutical industry. Suitable inks include the OPACODE® brand inks available from Colorcon of
30 West Point, PA. Other inks will be apparent to those of ordinary skill.

In a still further aspect of the invention there is provided a method of etching the markings onto the surface of pharmaceutical cores or compressed tablets. Laser-based etching systems are employed to impart the desired images onto the surface of the tablets.

5 In another preferred aspect of the invention there is provided the ability to print or etch onto or into various shape tablets preferably with a debossed printing or etching surface and preferably a debossed flat printing or etching surface for the purposes of:

enhancing the resolution and printability or etching of the bar code into or onto the surface of the tablet and / or subsequent film coating; and /or depressing the logo below the surrounding surface of the tablet.

10 The oral solid dosage forms of this embodiment thus include a core or tablet surface having a debossed or recessed region into which the printed or etched marking is placed. The debossed region preferably has a substantially horizontal plane with respect to the center of said core and thus provides a flat or substantially flat area into which the markings can be placed. The debossed region can be made using a properly selected
15 tablet tooling set having a convex punch on at least one of the upper and lower dies. The tablets containing the debossed region are then directed to the printer, such as via a conveyor system after being oriented to allow the recessed region to receive the printed marking.

The depressed logo and markings into the tablet provides the following benefits:
20 protection from wear and abrasion of the bar code due to tablet handling equipment, packaging and prescription filling processes and equipment.

This invention is, however, not limited to the etching or imprinting into or onto a debossed flat surface, but also includes the imprinting or etching onto or into the surface of a flat or rounded or other shaped tablet surface.

25 The invention includes the ability to deboss the outline of a logo or tradename or symbol into the tablet to enhance identification of the tablet while providing a depressed and preferably flat surface for the imprinting or etching of the bar code onto or into the surface of a tablet or film coated tablet or other solid dose form.

30 The invention also includes the combination of color film coated tablets to enhance the identification of the tablet in preference with a color imprinted logo, symbol, tradename and / or bar code.

The invention includes the use of film coatings and or color film coatings to enable laser etching onto the surface of the tablet to create a multi-color logo or otherwise identification onto or into the solid dose form.

5 The invention can also include the use of film coatings and or color film coatings to enhance the adhesion and / or cohesion of an ink or other pigmented system into and or onto the surface of the film coated tablet or other solid dose form.

The invention includes the combination of the above combined with unique tablet shapes or unique color and tablet shape combinations to further enhance the identification of the tablet and / or drug.

10 The invention allows for the ready visual identification of the drug via its unique color and or shape and or markings such as a logo and / or symbol and or its debossed impressions and / or in combination with any or all of the preceding attributes of the tablet.

The invention includes the ability to electronically scan a tablet to readily identify the tablet and or drug. Such techniques are known to those of ordinary skill, see, for example US Patent Nos. 5,992,742 and 6,543,692, the disclosure of each of which is incorporated herein by reference.

20 The invention includes the stand alone identification of the drug through visual means, the stand alone identification of the drug through electronic scanning means and or the combination of identification through visual and electronic means.

The invention includes the use of visible and or invisible pigments, colors and or inks to enable identification by light sources and scanning systems that do not rely upon visible light waves. Additionally, the invention includes other detection equipment not dependent upon light waves such as chromatographic based or other analytical techniques to detect aroma and or taste, but not limited to aroma and or taste. Such other methods may include other types of Markers as discussed below.

Covert Markers

30 The invention includes the use of covert markers in and or on tablets, in and or on film coatings and in or on inks or other pigment systems either visible or invisible to the human eye when applied to solid dose forms. The authentication systems are globally

approved covert markers, and evidentially robust for loss prevention and protection concerns, as well as providing measures of patient and national security. The systems have been proven compatible and stable with color film coated systems for solid dosage form pharmaceutical and nutritional supplement applications.

5 Covert markers contemplated for use herein include those available from Biocode of Bethlehem, PA and described, for example in US Patent No. 5,942,444, the disclosure of which is incorporated herein by reference. The amount of the covert marking included will depend upon several factors including the specific marking selected, the tablets being treated, etc. For example, the covert marking can be included as part of the film coating
10 or ink used for the marking of the tablets. Preferably, however, the covert marking is applied to the tablet as part of the film coating with amounts of about 5 parts per million (ppm)/ tablet.

These covert markers cannot usually be detected by the human senses, and extremely difficult if not impossible to detect through normal analytical techniques. The
15 markers can be incorporated into a solid dosage film coating to enshroud the solid dose form thereby providing a continuous security "package" in the form of a coating around the solid dose form. The covert marking system thus provides information amounting to a "chemical bar code" to render data such as source of manufacture, date of expiration, channel of distribution, origin, etc. Hence, the covert marker can serve as a carrier of
20 information that extends beyond the NDC code which is contained in the 2D bar code on the surface of the film coated tablet or other solid dose form. Analysis of the covertly marked tablet can be done using the Biocode lateral flow device (LFD) to provide a quick qualitative visual confirmation of the presence of the marker. In use, the surface of the tablet suspected of containing the covert marking is wetted with a small amount of water
25 and a portion of the run off is processed with the LFD to confirm the presence of the covert marker. If desired, additional confirmation of the presence of the marker can be had using other chromatographic methods including HPLC or GC, etc.

The covert markers can also be used to identify the film coating, and/or ink and/or
30 other pigmented systems applied to or contained within the tablet as well as other excipients in the tablet and/or the drug / active ingredient contained within or on the solid dosage form.

This invention includes the use of covert markers alone or in combination with any of the described overt technologies discussed above or in combination with any combination of the described overt technologies discussed above.

5 **EXAMPLES**

Example 1

Color Contrast Evaluation between 2-D Bar Code Inks and Color Film Coated Solid Dosage Forms

10 In this example, the feasibility of combining colored bar code ink applied to color film coated tablets was undertaken to determine color contrast requirements or limitations. The photographs attached hereto as Figures 1-2 provide the color combinations that have been tested and successfully scanned. A variety of placebo compressed cores (tablets), about 400mg each, having a range of shapes and colors were
15 top coated to a weight gain of about 3% using Opaglos® 2 (Colorcon) to one of the colors set forth in the Table below. The barcode was applied to the tablets using an Opacode® (Colorcon) ink in the colors shown in the Table using a Printing International pad printer model PI/290 Pa.

 The following chart indicates the variety of bar code ink colors that can be
20 combined with color film coated tablets and scanned using an Intermec Technologies high density Model 1470 scanner. To aid the reader, two examples of how to interpret the table below are provided:

1. A black ink color was scanned successfully on a white color film coated tablet 5 out of 5 times.
- 25 2. Black bar code ink on a purple film coated tablet was not successfully scanned due to the lack in color contrast between the bar code and the tablet surface color.

Color of Film Coated Tablet

<u>Color of Ink</u>	<i>White</i>	<i>Red</i>	<i>Purple</i>	<i>Yellow</i>
Black	5/5	5/5	0/5	5/5
White	-	0/5	5/5	0/5
Yellow	0/5	0/5	0/5	-
Grey	0/5	0/5	0/5	0/5
Brown	5/5	5/5	0/5	5/5
Red	5/5	0/5	0/5	5/5
Blue	5/5	5/5	0/5	5/5
Green	5/5	5/5	0/5	0/5

Example 2**Imprinting 2-D Bar Codes on Film Coated Tablets of Various Shapes**

5

The minimum size of bar code for an NDC code was found to be 2.5 sq. mm when a black ink was printed onto a white flat faced tablet although this increased to 3.0 sq. mm when printed onto curved tablets and 4.0 sq. mm when on colored tablets; i.e.:

Tablet Size	Round flat faced tablets (13mm)	Round normal curvature tablets (10mm)	Round concave tablets (6.35mm)	Caplets (19 x 7mm)	Round concave tablets (9.53mm)	Round double radius tablets (9.53mm)
Minimum Size Bar Code (Sq. mm)	2.5	3.0	3.0	4.0	4.0	4.0

10

Example 3

5 In this example, the process of Example 1 is repeated except that a covert marker is included in the film coating. Specifically, 0.04 wt% of a Biocode marker is added to the Opaglos 2 suspension before it is applied to the tablets. The final product is determined to have about 5 ppm of the covert marking per tablet.

Examples 4-5

10 In these examples, the procedures of Examples 1 and 3 are repeated except that an ink jet printer is employed in place of the pad printer.

Examples 6-7 Serialization of 2D Bar Coded Imprints

15 In these examples, the procedures of Examples 4-5 are repeated except that the ink jet printer is modified to allow the individual tablets to be consecutively numbered (serialized) so that each tablet has a unique number.

Example 8

20 In this example, the covertly marked tablets of Example 3 are tested using the LFD device of Biocode. Specifically, one of the tablets is wetted with water and the run off is directed to an LFD device and the presence of the marker is qualitatively confirmed.

25

Minimum Size Limitations of 2-D Bar Codes

The minimum size of the bar code required depends upon a number of factors; e.g.: number of digits being coded, resolution of scanner, curvature of substrate, and degree of color contrast between ink and substrate. The minimum size bar code that can contain the NDC code is 2.5 mm square. It is possible to reduce the size of the bar code further if the full NDC code is not required. The limits of the high-resolution bar code

30

60477561.061103

scanner may then be the determining limit for the minimum size of the 2-D data matrix bar code.

Reliability of 2-D Data matrix Bar Code Symbology

- 5 2D Data matrix bar codes are robust and readable even when there is only a partial image present - we found we could lose some of the code within the border and still successfully scan.

10

What is claimed is:

1. An oral solid dosage form, comprising
 - a) a core portion having sufficient friability to receive a printed or etched marking on a surface thereof;
 - b) a readable printed or etched marking on the surface of said core, said marking providing identification/authentication of said oral dosage form.
2. The oral solid dosage form of claim 1, wherein said core is film coated prior to said printed or etched marking being applied thereto.
3. The oral solid dosage form of claim 1, wherein said printed or etched marking is a bar code.
4. The oral solid dosage form of claim 3, wherein said bar code is a 2D data matrix bar code.
5. The oral solid dosage form of claim 2, wherein said film coat is contains a coloring.
6. The oral solid dosage form of claim 1, wherein said marking is readable with a bar code scanner.
7. The oral solid dosage form of claim 1, wherein said marking is readable with detection equipment which does not depend upon visible light waves.
8. The oral solid dosage form of claim 1, further comprising a covert marking thereon.
9. The oral solid dosage form of claim 1, wherein said covert marking is detectable by aroma or taste.

10. The oral solid dosage form of claim 8, wherein said covert marking is detectable using HPLC.

5 11. The oral solid dosage form of any of claims 1-10, wherein the surface of said core further comprises a debossed region into which said printed or etched marking is placed.

12. The oral solid dosage form of claim 11, wherein said debossed region has a substantially horizontal plane with respect to the center of said core.

10

13 The oral solid dosage form of claim 1, wherein said core has an ink coating applied to a portion thereof prior to said marking being applied thereto.

14. A method of applying a readable printed or etched marking which provides
15 identification/authentication criteria on the surface an oral solid dosage form, comprising
a) providing a pharmaceutically acceptable core portion having sufficient friability to receive a printed or etched marking on a surface thereof;
b) applying a readable printed or etched marking on the surface of said core.
said marking of said oral dosage form.

20

15. The method of claim 14, wherein said marking is applied via pad printing.

16. The method of claim 14, wherein said marking is applied via ink jet printing.

25 17. The method of claim 14, wherein said marking is etched onto a surface of said core.

18. The method of claim 14, further comprising debossing a surface region of said core and applying said marking in said debossed region.

30


19. The method of claim 14, further comprising film coating the surface of said the core prior to applying said marking.
20. The method of claim 14, further comprising applying a covert marking to said
5 core .
21. The method of claim 20, wherein said printed marking is applied using an ink containing a covert marker therein.
- 10 22. The method of claim 15, wherein said pad printing is applied using an Opacode ink.
23. The method of claim 20, wherein the concentration of said covert marker is applied to the film coating in an amount sufficient to provide about 2 to about 5 ppm per
15 tablet marked.
24. The method of claim 23, wherein the concentration of said covert marker is sufficient to provide about 4 ppm per tablet marked.

ABSTRACT

Oral solid dosage forms such as tablets having overt, printed or etched markings as well as optional covert markings are disclosed. The markings can be rapidly identified to authenticate a dosage form and/or drug contained therein. The inventive dosage forms include a core portion having sufficiently low friability to receive a printed or etched marking on a surface thereof; and a readable or detectable printed or etched marking on the surface of the core which provides information allowing the identification / authentication of the oral dosage form. In preferred aspects of this embodiment, a bar code, more preferably, a 2D data matrix bar code is printed or etched on a debossed region on the surface of the solid dose form. Methods of preparing the marked dosage forms and methods of identifying and/ or authenticating solid dosage forms are also disclosed.

60477561.061103

FIGURE 1



60477561.061103

FIGURE 2

